OPEN END TURBO OHNE STOP-LOSS - NOVO-NORDISK B | Market Closed - Börse Stuttgart 11:44:22 05/07/2024 am IST | ||
| 14.99 EUR | +1.01% |
|
| Current month | -7.41% | ||
| 1 month | -1.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 14.99 | +1.01% |
| 04/24/04 | 14.84 | -4.63% |
| 03/24/03 | 15.56 | -4.48% |
| 02/24/02 | 16.29 | +2.13% |
| 01/24/01 | 15.95 | -1.48% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 11:44 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Lang & Schwarz |
| WKN | LX2G60 |
| ISIN | DE000LX2G606 |
| Date issued | 06/10/2022 |
| Strike | 54.39 € |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.47 € |
|---|---|
| Lowest since issue | 0.67 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Certificates
- Certificat
